tadalafil and ambrisentan upfront combination therapy
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease, Pulmonary Hypertension
Trial Timeline
Jan 1, 2010 → Nov 1, 2014
NCT ID
NCT01042158About tadalafil and ambrisentan upfront combination therapy
tadalafil and ambrisentan upfront combination therapy is a approved stage product being developed by Eli Lilly for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01042158. Target conditions include Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01042158 | Approved | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension